Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BIIB122 phase 2b trial in early Parkinson's disease without pathogenic LRRK2 variants
MOH_2023-01-16_012289Phase 2Active, not recruiting
- Sponsor
- Biogen
- Start
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Parkinson's disease (PD) comparing BIIB122 225 mg with matching placebo (2 arms). Started Dec 2022; status: active, not recruiting.
02
Drugs
BIIB122
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on MOH_2023-01-16_012289.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2023-01-16_012289.